Clinical effects of a hypercaloric and hyperproteic oral suplemment enhanced with w3 fatty acids and dietary fiber in postsurgical ambulatory head and neck cancer patients

• Autores: Daniel Antonio de Luis Román, Beatriz de la Fuente Salvador, Olatz Izaola Jáuregui, Tomas Martin Gonzalez, Luis Ángel Cuéllar Olmedo, María Concepción Terroba Larumbe
• Localización: Nutrición hospitalaria: Organo oficial de la Sociedad española de nutrición parenteral y enteral, ISSN-e 1699-5198, ISSN 0212-1611, Vol. 31, Nº. 2, 2015, págs. 759-763
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Dialnet Métricas: 1 Cita
• Resumen

  • Background: Patients with head and neck cancer undergoing surgery have a high risk of nutritional complications.

    Objective: The aim of our study was to investigate the influence of a hypercaloric and hyperproteic oral supplement enriched with w3 FATTY ACIDS and fiber in clinical parameters in head and neck tumor postsurgical ambulatory patients with or without radiotherapy.

    Design: A population of 37 ambulatory postsurgical patients with oral and laryngeal cancer was enrolled. At Hospital discharge postsurgical head and neck cancer patients were asked to consume two units per day of a hypercaloric and hyperproteic oral supplement for a twelve week period.

    Results: The mean age was 63.8+/-7.1 years (16 female/21 males). Duration of supplementation was 98.1±19.1 days. A significant increase of albumin and transferrin levels was observed, in total group and in patients undergoing radiotherapy and without it. No differences were detected in weight and other anthropometric parameters in total group and in patients with radiotherapy during the protocol. Nevertheless, patients without radiotherapy showed a significant improvement of BMI; weight, fat free mass and fat mass.

    Conclusions: An omega 3 and fiber enriched formula improved seric protein levels in ambulatory postoperative head and neck cancer patients. Improvement of weight, fat mass and fat free mass was observed in patients whom not received radiotherapy during the follow up.